Mavorixafor

About X4 Pharmaceuticals

X4 Pharmaceuticals, founded in 2015, is a Boston-based biotech with a mission of 'Rare Resolve' to develop and commercialize therapies for rare immune diseases. The company achieved a pivotal milestone with the April 2024 FDA approval and subsequent U.S. launch of XOLREMDI® for WHIM syndrome, validating its CXCR4 platform. Its strategy is to build a sustainable commercial foundation in WHIM syndrome while aggressively pursuing label expansion into chronic neutropenic disorders through a pivotal Phase 3 trial, supported by strategic ex-U.S. partnerships.

About X4 Pharmaceuticals

X4 Pharmaceuticals, founded in 2015, is a Boston-based biotech with a mission of 'Rare Resolve' to develop and commercialize therapies for rare immune diseases. The company achieved a pivotal milestone with the April 2024 FDA approval and subsequent U.S. launch of XOLREMDI® for WHIM syndrome, validating its CXCR4 platform. Its strategy is to build a sustainable commercial foundation in WHIM syndrome while aggressively pursuing label expansion into chronic neutropenic disorders through a pivotal Phase 3 trial, supported by strategic ex-U.S. partnerships.

Therapeutic Areas